drugset / Trial / NCT06649136
MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients with Active Rheumatoid Arthritis
Phase 4
Recruiting
182 enrolled
Medical University of Vienna
Diakonhjemmet Hospital · collabKarolinska Institutet · collabLeiden University Medical Center · collabQueen Mary University of London · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The MethMax trial is a prospective, international, multicentre, randomised, assessor-blinded, parallel-group, low intervention study. Patients with active rheumatoid arthritis treated with oral methotrexate up to 25mg weekly will be randomised in 50:50 fashion to receive 25mg oral vs subcutaneous methotrexate for the period of 24 weeks. In regular visits, patient reported outcomes, clinical disease activity, therapy adherence and diverse established and exploratory biomarkers will be assessed.
Timeline
- Start
- 2024-08-12
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methotrexate | Small molecule | 25 mg | Oral |